Home/Pipeline/CAR-T Response Model

CAR-T Response Model

B-Cell Lymphoma

ResearchActive

Key Facts

Indication
B-Cell Lymphoma
Phase
Research
Status
Active
Company

About Quibim

Quibim is a Valencia-based leader in the radiomics and quantitative imaging AI space, operating a secure, cloud-native platform (QP-Insights®) that harmonizes, manages, and analyzes large-scale imaging and multi-omics data. The company has a dual business model: it offers AI-powered diagnostic software (QP-Prostate, QP-Brain, QP-Liver) to healthcare providers and provides biomarker discovery and clinical trial analytics services to biopharma partners. With ISO 27001 certification and a focus on data security, Quibim leverages one of the world's largest de-identified imaging registries to build predictive models aimed at accelerating drug development and improving patient outcomes in precision medicine.

View full company profile

Other B-Cell Lymphoma Drugs

DrugCompanyPhase
CD19 CAR-TBinDeBioClinical
VNX-103Vironexis BiotherapeuticsIND-Enabling
ELC-301Elicera TherapeuticsPhase I/II